FRAXA background

Drs. Oostra, Warren, and Nelson discovered the Fragile X gene and its FRAXA mutation in 1991.

Newsroom

Look here for the latest discoveries and announcements

How Close are we to a Cure?

Progress and major challenges, our strategy and 2015 goals

Fragile X Research Funded

More than a dozen teams have received 2015 FRAXA funding. Browse them here.

Working toward a Cure

FRAXA’s mission is to find effective treatments and a cure for all children and adults with Fragile X, by directly funding the most promising research. As the pace of Fragile X research accelerates, the prospects of finding effective treatments and a cure for Fragile X and autism continue to improve. FRAXA-funded researchers at universities around the world are leading the way.

FRAXA Strategy

FRAXA’s research portfolio spans the spectrum of translational, pre-clinical, and clinical research — all coordinated to make the most of each dollar. We maintain a diversified approach, developing several treatment strategies in parallel, since success is never certain in developing a single drug.

Look here for latest news about Fragile X treatment advances, research discoveries, families and FRAXA in the news.
Read More

FRAXA-funded research has progressed from understanding the cause of Fragile X to Phase III clinical trials of targeted medicines.
Read More

Clinical trials are in progress and seeking participants in the US and in Europe. Trials of available drugs and investigational new drugs are both underway.
Read More

Research is accelerating, and prospects of finding treatments and a cure for Fragile X and autism continue to improve. FRAXA is leading the way.
Read More